Patent Scope and Claims Map for US Drug Patent 8,129,343 (SEQ ID NO: 7; GLP-1-(7-37); Type 2 Diabetes)
US Drug Patent 8,129,343 is claim-layered around (i) a specific peptide sequence defined by SEQ ID NO: 7, (ii) a specific identified peptide with the full chemical name reciting a long-chain lipid conjugate plus a GLP-1-(7-37) core with Aib8 and Arg34 substitutions, and (iii) treatment of type 2 diabetes via administration of a pharmaceutical composition containing that same peptide. The estate’s practical enforceability turns on whether an accused product contains the claimed peptide (or a composition that includes it) and whether the label/clinical use fits the claimed method for type 2 diabetes.
What patents protect GLP-1-(7-37) lipid-conjugate peptides with SEQ ID NO: 7?
Direct claim coverage in 8,129,343 centers on two invention embodiments: a “compound of the structure” whose peptide is defined by amino acid identity to SEQ ID NO: 7 (claims 1 and 2) and a specific named compound that corresponds to a GLP-1-(7-37) lipid conjugate with Aib8 and Arg34 (claims 4 and 5). Type 2 diabetes treatment methods follow in claims 3 and 6.
How claim 1 constrains scope: “compound” by structure plus amino-acid sequence
Claim 1 is drafted as a structural claim tied to an amino acid sequence identity: a compound having a structure where the amino acid sequence is that of SEQ ID NO: 7.
Key scope implications:
- Sequence-defined peptide core is required. Even if the lipid tail or linker differs, an accused compound must still satisfy the “amino acid sequence is that of SEQ ID NO: 7” requirement.
- The phrase “of the structure” indicates additional structural constraints beyond the sequence. Sequence alone is typically not enough when the claim recites “compound of the structure” and then anchors the sequence. That usually means the lipid conjugation and/or linker architecture in SEQ ID NO: 7’s described structure is part of what must be present to infringe.
- Markush-style breadth vs literal equivalence: Because claim 1 is “a compound of the structure where the amino acid sequence is that of SEQ ID NO: 7,” infringement typically requires matching the structure as claimed, not just any GLP-1 analog with a similar pharmacology.
How claim 4 narrows coverage: a single chemically identified peptide
Claim 4 recites a specific named compound:
- “N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)peptide.”
Key scope implications:
- This is a very specific chemical species claim. It typically offers high specificity for enforcement against products that use that exact lipid conjugate/linker construct.
- It also provides a clean claim mapping for product comparison: accused peptide can be assessed against whether it is the same named entity, not just whether it has the same biological target.
Claims 2 and 5: composition protection tied to the same active
Claim 2: pharmaceutical composition comprising the SEQ ID NO: 7 peptide and a pharmaceutically acceptable excipient.
Claim 5: pharmaceutical composition comprising the named Aib8/Arg34 GLP-1-(7-37) lipid conjugate and a pharmaceutically acceptable excipient.
Key scope implications:
- Excipient choices are not limiting so long as they are “pharmaceutically acceptable.” That tends to broaden practical infringement because most injectable formulations qualify.
- Biosimilar/generic formulation design does not avoid infringement if the active peptide is within the claim.
Claims 3 and 6: method-of-use tied to type 2 diabetes
Claim 3: method for treating type 2 diabetes by administering an effective amount of the SEQ ID NO: 7 composition.
Claim 6: the same method but with the named peptide composition.
Key scope implications:
- Method claims hinge on (i) administration of the claimed composition and (ii) treatment for “type 2 diabetes”.
- If a product is used off-label for type 1 diabetes or obesity without diabetes, it can create a defense on the “for treating type 2 diabetes” limitation, depending on facts and evidence of intended use.
How does SEQ ID NO: 7 compare with the named Aib8, Arg34 GLP-1-(7-37) conjugate?
Featured snippet answer: Claim 1 and claim 4 cover the same invention space but in two claim styles: claim 1 covers any “compound of the structure” that includes the peptide defined by SEQ ID NO: 7, while claim 4 covers the explicitly named lipid-conjugated [Aib8,Arg34]GLP-1-(7-37) peptide with the stated linker and long-chain lipid moiety.
What is protected by the SEQ ID approach?
- SEQ ID NO: 7 is the sequence anchor. If an accused peptide matches the sequence, it is harder to avoid infringement using substitutions elsewhere only if the “structure” requirement is also met.
- In many peptide patents, the SEQ ID sequence defines the core peptide, while the lipid and linker are separately defined. Claim 1’s “compound of the structure” signals that the lipid-linker scaffold is still part of what must match.
What is protected by the chemical name approach?
- The chemical name in claim 4 includes the lipid chain length and the linker pattern, plus the Aib8 and Arg34 substitutions.
- A product with the same GLP-1 core sequence but a different lipid chain length or linker is more likely to fall outside claim 4, but may still be tested under claim 1 depending on how “structure” is interpreted.
What does “pharmaceutically acceptable excipient” add to infringement risk?
Featured snippet answer: Excipient language makes claims 2 and 5 hard to design around by formulation-only changes.
Practical scope effects:
- If the active peptide matches claim 1 or claim 4, almost any approved injectable excipient set is likely “pharmaceutically acceptable.”
- Reformulation, buffering, tonicity agents, and standard peptide stabilizers typically do not avoid infringement. Avoidance generally requires changing the active or removing it from the claimed peptide.
When does US Drug Patent 8,129,343 lose exclusivity?
No answer provided. Without the patent’s issue date, earliest priority date, listed drug product, and whether patent term adjustment (PTA) or patent term extension (PTE) under 35 USC 156 is implicated, an exclusivity and expiration timeline cannot be computed accurately from the claim text alone.
What Orange Book status and FDA regulatory milestones matter for this patent?
No answer provided. Determining Orange Book listings requires the patent-to-product mapping (drug name/NDA/BLA) and the Orange Book reference ID. The claim text alone does not provide that regulatory linkage.
What generic or biosimilar entry risks exist for products covering SEQ ID NO: 7?
No complete infringement risk assessment is possible from claims alone. A credible generic entry-risk analysis requires knowing whether any ANDA has been filed, whether the active peptide is the same species, and how FDA labels and product compositions map to the claimed compound. The claim set you provided does not identify the marketed drug, reference product, or application.
How strong is the patent estate for the SEQ ID NO: 7 GLP-1 lipid conjugate?
Claim-strength indicators from the claim language
- Direct compound claims (1, 4): species-level peptide coverage tends to be enforceable against products containing that exact peptide or structure.
- Composition claims (2, 5): formulation changes are less likely to avoid infringement if the peptide is the same.
- Method claims (3, 6): provide additional leverage tied to indication, but can be more fact-dependent in litigation.
Potential vulnerability points (litigation posture)
- If an accused product uses a different lipid chain length, linker length, or conjugation point, the “compound of the structure” requirement in claim 1 and the exact identity in claim 4 become central. A litigated claim construction could narrow or broaden the interpretation of “structure” elements.
- Method claims often face enforcement and evidentiary issues tied to label, prescribing, and “in need of such treatment.”
How many patents cover this same SEQ ID NO: 7 peptide?
No answer provided. Counting related patents requires a full patent landscape search using the peptide sequence identifier (SEQ ID NO: 7), assignee, and family members. The claim text alone does not provide the patent family, assignee, priority, or related publications.
What patent litigation affects US Drug Patent 8,129,343?
No answer provided. Litigation status cannot be determined from claim text alone; it requires case dockets, parties, and asserted-reference mappings.
Key Takeaways
- US Drug Patent 8,129,343 protects a GLP-1-(7-37) lipid-conjugated peptide defined in two ways: by SEQ ID NO: 7 (claims 1 and 2) and by a fully specified Aib8,Arg34 GLP-1-(7-37) lipid conjugate name (claims 4 and 5).
- The patent also covers pharmaceutical compositions comprising the claimed peptide plus typical excipients (claims 2 and 5), making formulation-only design-arounds less effective.
- It includes type 2 diabetes treatment method claims tied to administering the claimed compositions (claims 3 and 6), creating indication-specific leverage.
- Scope and enforceability in practice will turn on whether an accused product’s active peptide identity and structural conjugation elements match the claimed species and structure.
FAQs
- Can a product avoid infringement by changing only excipients in a GLP-1-(7-37) lipid conjugate?
- What does “compound of the structure” require beyond matching SEQ ID NO: 7?
- How do claim 1 (SEQ ID) and claim 4 (named chemical) differ for design-around strategy?
- What evidence is typically used to support infringement of method claims for “treating type 2 diabetes”?
- If a biosimilar uses a different lipid tail length, does it evade claim 4 while still risking claim 1?
References
No references provided because no source documents beyond the claim excerpt were provided, and the question requires landscape and regulatory/legal mappings that cannot be grounded without citing the underlying patent record, Orange Book listings, and litigation dockets.
